 Theresa Pacheco
Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 10 | 2022 | 805 | 0.910 |
Why?
| | Immunocompromised Host | 2 | 2019 | 201 | 0.690 |
Why?
| | Lentigo | 2 | 2015 | 6 | 0.640 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 4 | 2022 | 43 | 0.630 |
Why?
| | Tumor Suppressor Proteins | 3 | 2024 | 314 | 0.550 |
Why?
| | Carcinoma | 1 | 2019 | 225 | 0.510 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2010 | 55 | 0.320 |
Why?
| | Mycosis Fungoides | 2 | 2022 | 63 | 0.310 |
Why?
| | Tetracycline | 2 | 2000 | 11 | 0.300 |
Why?
| | Skin Aging | 2 | 2026 | 20 | 0.300 |
Why?
| | Cafe-au-Lait Spots | 1 | 2007 | 2 | 0.260 |
Why?
| | Intestinal Polyps | 1 | 2007 | 12 | 0.250 |
Why?
| | Incontinentia Pigmenti | 1 | 2006 | 3 | 0.240 |
Why?
| | Cosmetic Techniques | 1 | 2026 | 19 | 0.240 |
Why?
| | Skin Care | 1 | 2025 | 22 | 0.220 |
Why?
| | Face | 1 | 2026 | 177 | 0.210 |
Why?
| | LEOPARD Syndrome | 1 | 2004 | 2 | 0.210 |
Why?
| | Dermatologic Agents | 1 | 2025 | 69 | 0.210 |
Why?
| | Hair Color | 1 | 2024 | 14 | 0.210 |
Why?
| | Noonan Syndrome | 1 | 2004 | 14 | 0.210 |
Why?
| | Hyperpigmentation | 1 | 2024 | 26 | 0.200 |
Why?
| | Melanocytes | 1 | 2024 | 57 | 0.200 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 66 | 0.200 |
Why?
| | Plasmacytoma | 1 | 2003 | 19 | 0.200 |
Why?
| | Cosmetics | 1 | 2025 | 76 | 0.190 |
Why?
| | Melanoma | 4 | 2007 | 764 | 0.190 |
Why?
| | Photochemotherapy | 1 | 2022 | 39 | 0.180 |
Why?
| | Lupus Erythematosus, Discoid | 1 | 2002 | 5 | 0.180 |
Why?
| | Lupus Erythematosus, Cutaneous | 1 | 2000 | 7 | 0.160 |
Why?
| | Angioedema | 1 | 2000 | 16 | 0.160 |
Why?
| | Trans-Activators | 2 | 2000 | 371 | 0.150 |
Why?
| | Genetic Linkage | 2 | 2015 | 269 | 0.150 |
Why?
| | Parvovirus | 1 | 1999 | 13 | 0.150 |
Why?
| | Hydroxamic Acids | 2 | 2009 | 95 | 0.140 |
Why?
| | Pedigree | 3 | 2024 | 507 | 0.120 |
Why?
| | Heart Transplantation | 1 | 2003 | 679 | 0.120 |
Why?
| | Cell Cycle Proteins | 1 | 2000 | 629 | 0.110 |
Why?
| | Lung Transplantation | 1 | 2019 | 326 | 0.110 |
Why?
| | Carrier Proteins | 1 | 2000 | 728 | 0.110 |
Why?
| | Humans | 23 | 2026 | 145625 | 0.110 |
Why?
| | Diagnosis, Differential | 3 | 2006 | 1500 | 0.110 |
Why?
| | Hyperthermia, Induced | 2 | 2007 | 119 | 0.110 |
Why?
| | Delphi Technique | 2 | 2026 | 347 | 0.100 |
Why?
| | Mosaicism | 2 | 2006 | 67 | 0.100 |
Why?
| | Male | 14 | 2024 | 73014 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 1999 | 1429 | 0.090 |
Why?
| | Phenotype | 2 | 2024 | 3186 | 0.090 |
Why?
| | Facial Neoplasms | 1 | 2011 | 19 | 0.080 |
Why?
| | Doxycycline | 2 | 2000 | 61 | 0.070 |
Why?
| | Adenoma | 1 | 2011 | 209 | 0.070 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 149 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1324 | 0.070 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2009 | 218 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2000 | 878 | 0.070 |
Why?
| | Transfection | 2 | 2000 | 914 | 0.060 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2007 | 38 | 0.060 |
Why?
| | Karyotyping | 1 | 2006 | 106 | 0.060 |
Why?
| | Salvage Therapy | 1 | 2007 | 163 | 0.060 |
Why?
| | Tooth Abnormalities | 1 | 2006 | 17 | 0.060 |
Why?
| | Female | 11 | 2024 | 79080 | 0.060 |
Why?
| | Nervous System Malformations | 1 | 2006 | 46 | 0.060 |
Why?
| | Glycolates | 1 | 2025 | 6 | 0.060 |
Why?
| | Benzoyl Peroxide | 1 | 2025 | 2 | 0.060 |
Why?
| | Salicylic Acid | 1 | 2025 | 10 | 0.060 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 268 | 0.060 |
Why?
| | Dermatologists | 1 | 2025 | 7 | 0.060 |
Why?
| | Dicarboxylic Acids | 1 | 2025 | 12 | 0.060 |
Why?
| | Retinoids | 1 | 2025 | 34 | 0.050 |
Why?
| | Sunscreening Agents | 1 | 2025 | 25 | 0.050 |
Why?
| | Acne Vulgaris | 1 | 2025 | 25 | 0.050 |
Why?
| | Lod Score | 1 | 2004 | 62 | 0.050 |
Why?
| | Middle Aged | 7 | 2022 | 36359 | 0.050 |
Why?
| | Consensus | 1 | 2026 | 465 | 0.050 |
Why?
| | Niacinamide | 1 | 2025 | 103 | 0.050 |
Why?
| | Nevus, Pigmented | 1 | 2004 | 35 | 0.050 |
Why?
| | Adult | 6 | 2024 | 40821 | 0.050 |
Why?
| | Equipment Failure Analysis | 1 | 2004 | 124 | 0.050 |
Why?
| | Eosinophils | 1 | 2006 | 319 | 0.050 |
Why?
| | Eczema | 1 | 2004 | 66 | 0.050 |
Why?
| | Ascorbic Acid | 1 | 2025 | 183 | 0.050 |
Why?
| | Dermatology | 1 | 2025 | 131 | 0.050 |
Why?
| | Forearm | 1 | 2003 | 141 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2026 | 11744 | 0.050 |
Why?
| | Perylene | 1 | 2022 | 6 | 0.050 |
Why?
| | Ointments | 1 | 2022 | 24 | 0.050 |
Why?
| | Anthracenes | 1 | 2022 | 31 | 0.050 |
Why?
| | Specimen Handling | 1 | 2004 | 178 | 0.050 |
Why?
| | Cell Lineage | 1 | 2024 | 375 | 0.040 |
Why?
| | Photosensitizing Agents | 1 | 2022 | 42 | 0.040 |
Why?
| | Mutation | 2 | 2006 | 4082 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2026 | 698 | 0.040 |
Why?
| | Neurofibromatosis 1 | 1 | 2002 | 59 | 0.040 |
Why?
| | Aged | 3 | 2019 | 26251 | 0.040 |
Why?
| | Cell Culture Techniques | 1 | 2004 | 371 | 0.040 |
Why?
| | Skin | 1 | 2006 | 701 | 0.040 |
Why?
| | Hot Temperature | 1 | 2004 | 396 | 0.040 |
Why?
| | Hydroxychloroquine | 1 | 2002 | 65 | 0.040 |
Why?
| | Thymidine Kinase | 1 | 2000 | 14 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2000 | 14 | 0.040 |
Why?
| | Retinoblastoma Protein | 1 | 2000 | 63 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2000 | 74 | 0.040 |
Why?
| | Diseases in Twins | 1 | 2000 | 114 | 0.040 |
Why?
| | Luciferases | 1 | 2000 | 153 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2026 | 1754 | 0.040 |
Why?
| | Simplexvirus | 1 | 2000 | 80 | 0.040 |
Why?
| | Colorado | 2 | 2007 | 4588 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1709 | 0.040 |
Why?
| | Lower Extremity | 1 | 2003 | 449 | 0.040 |
Why?
| | Apoptosis | 1 | 2007 | 2436 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 172 | 0.040 |
Why?
| | Plasmids | 1 | 2000 | 372 | 0.040 |
Why?
| | Transduction, Genetic | 1 | 1999 | 129 | 0.030 |
Why?
| | Clone Cells | 1 | 1999 | 259 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2002 | 483 | 0.030 |
Why?
| | Genes, Reporter | 1 | 1999 | 273 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 2218 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2018 | 302 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 662 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1999 | 368 | 0.030 |
Why?
| | Cell Cycle | 1 | 2000 | 595 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2000 | 1160 | 0.030 |
Why?
| | Child, Preschool | 2 | 2007 | 11888 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2006 | 6449 | 0.030 |
Why?
| | Mohs Surgery | 1 | 2011 | 30 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2591 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2007 | 3538 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1269 | 0.020 |
Why?
| | Adolescent | 1 | 2007 | 22451 | 0.020 |
Why?
| | Child | 1 | 2007 | 22638 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2007 | 140 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2007 | 216 | 0.020 |
Why?
| | Caspases | 1 | 2007 | 233 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2007 | 328 | 0.020 |
Why?
| | Probability | 1 | 2007 | 308 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 2007 | 200 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 782 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 867 | 0.010 |
Why?
| | Survival Analysis | 1 | 2007 | 1372 | 0.010 |
Why?
| | Feedback | 1 | 2004 | 180 | 0.010 |
Why?
| | Medical Records | 1 | 2004 | 190 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1486 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 2018 | 0.010 |
Why?
| | Equipment Design | 1 | 2004 | 519 | 0.010 |
Why?
| | Child Welfare | 1 | 2004 | 228 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2007 | 889 | 0.010 |
Why?
| | Temperature | 1 | 2004 | 633 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1102 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2007 | 5397 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 2497 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2004 | 3633 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2007 | 8351 | 0.010 |
Why?
| | Risk Factors | 1 | 2004 | 10840 | 0.000 |
Why?
| | Retrospective Studies | 1 | 2004 | 17291 | 0.000 |
Why?
|
|
Pacheco's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|